The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,300.00
Bid: 12,300.00
Ask: 12,302.00
Change: 182.00 (1.50%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Sunak's time to impress

Wed, 08th Jul 2020 10:12

* European shares slips

* Wall Street rose overnight

* UK's Sunak to map out next moves in recovery plan
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

SUNAK'S TIME TO IMPRESS (0909 GMT)

All eyes will be on UK's Sunak, who will unveil later today (around 1130 GMT) his plans to
revamp the economy as he tries to prevent the UK to fall into an unemployment crisis.

What shall we expect in terms of stocks reaction?

The quick answer is not much, as there has been a fair amount of reports anticipating some
of his planned moves, analysts suggest.

But fresh stimulus can always "have a positive impact" on the FTSE, says Ipek Ozkardeskaya,
senior analyst at Swissquote Bank.

Here're a few details on Sunak's plans:

- a 2 billion-pound fund to create six-month work-placement jobs for unemployed 16-24
year-olds.

- 3 billion pounds to improve the energy efficiency of homes and public buildings.

- he is reportedly considering a stamp duty holiday and giving away vouchers to boost
spending in hospitality businesses.

Some analysts' comments:

Deutsche Bank - "Our UK economists’ base case is that Sunak will broadly stick to the
mandate set out by PM Johnson last week, possibly topping up the package by another 0.2% of GDP,
focusing particularly on apprenticeship schemes, and modest wage subsidies to get furloughed
employees back into work".

UniCredit - "We certainly do not expect the government to extend the jobs retention scheme;
indeed, while the government accepts the likelihood of a big increase in job losses when the
scheme ends, it appears to have made a judgement that many of these jobs would ultimately be
lost anyway, and that it's better to support a reallocation of these workers to growth sectors".

LCG Research - "High hopes for more infrastructure spending, business grants or tax cuts
could quickly disappear if the focus remains on keeping jobs".

(Joice Alves)

*****

OPENING SNAPSHOT: WAIT AND SEE MOOD (0740 GMT)

European stocks are in negative territory as a surge in coronavirus cases in the U.S. has
clouded hopes for a swift economic recovery.

Investors are in a wait and see mood ahead of the upcoming earnings season, and next week's
ECB meeting and EU summit where leaders will discuss the recovery fund.

Britain's finance minister will announce later today his next moves to prevent a wave of job
cuts from snowballing into an unemployment crisis.

The STOXX 600 index is down 0.3% with banks leading losses down 1.2%, while oil and
gas shares drop 0.5% as oil prices dipped on renewed oversupply fears after data showed a build
in U.S. crude stockpiles.

Shares in Electrolux are among the best performers of the STOXX 600, up 6%, after
the company reported a smaller than expected loss. Victrex stocks, touched a
three-month lows, and are now down almost 4% after the company's trading update.

(Stefano Rebaudo)

*****

ON THE RADAR: INSURERS, BOOHOO, ASTRAZENECA, MERCK (0650 GMT)

European stocks are set for a session in the red, with investors in wait and see mode ahead
of the upcoming earnings session, while they are trying to assess if rising cases in the U.S.
will lead to more restrictive measures.

On the corporate front, commercial insurers are facing hefty claims from the coronavirus
crisis but are also seeing a steep rise in premiums – tempting companies and industry veterans
to raise capital, launch new businesses or expand into new lines. Lloyd's of London, insurers
Beazley, Hiscox and Lancashire are among those to raise equity.

AstraZeneca and Merck & Co said their blockbuster cancer treatment Lynparza
won approval in the European Union for treating patients with a form of pancreatic cancer.

Zalando will delist all products made by Britain's Boohoo following a
media report about dire working conditions in a English factory that supplied the popular brand.
Boohoo decided to launch an independent review of its supply chain in Britain.

Shares in Traton down 3.6% after the company announced management change.
Deutsche Post stocks up 1.3% in early trade after reporting a 16% rise
in second-quarter operating profit.

FirstGroup warned on its ability to continue as a going concern, after posting an
annual operating loss as passenger volumes plummeted due to the coronavirus crisis.

Electrolux said it will report a smaller loss for the second quarter of 2020 than
previously anticipated, with operating income estimated at about 100 million crown.

OMV Q2 output dropped 5% in wake of coronavirus pandemic.

Other headlines:

Diaceutics says sales for first half increased by 20%

Britain's Funding Circle to cut 85 U.S. jobs

Marlowe plc says FY adjusted profit before tax up 54%

Liontrust Asset Management says net inflows of £971 mln in 3 months ended 30 June 2020

Amigo Holdings appoints Glen Crawford as CEO

Italy's Stefanel draws 4 expressions of interest, expects more

(Stefano Rebaudo)

*****

MORNING CALL: NOT MUCH TO LOOK FORWARD TOO (0545 GMT)

European bourses seem poised to open in negative territory this morning with little to look
forward to after Asia and Wall Street failed to gain momentum and switched to 'wait-and-see'.

Futures for pan-European blue chips, the DAX and the FTSE were down 0.7%, 0.6% and 0.8%
respectively.

The resurgent coronavirus pandemic is keeping Wall Street in check while in Asia, the
bullishness surrounding Chinese shares failed to spread significantly across beyond the region.

Very little macro indicators or corporate events in Europe today to help markets find their
way.

Looking forward, investors will be eager to get into the Q2 earnings season to see for
themselves if the V-shaped recovery priced in the market is indeed on its way.

(Julien Ponthus)

*****

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.